April 24, 2019

Saiid Zarrabian
President and Chief Executive Officer
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, BC, Canada V5Z 1K5

       Re: DelMar Pharmaceuticals, Inc.
           Registration Statement on Form S-1
           Filed April 18, 2019
           File No. 333-230929

Dear Mr. Zarrabian:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment. In our comment, we may ask you to provide us with
information so
we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to the comment, we may have additional comments.

Registration Statement on Form S-1 filed on April 18, 2019

Cover page

1.     We note your disclosure that the rights offering will expire on or about
a certain date, and
       that you may extend the rights offering for additional periods in your
sole discretion.
       Please revise your disclosure to provide an expiration date for the
rights offering that is
       not indefinite. Refer to Item 501(b)(8)(iii) of Regulation S-K.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 Saiid Zarrabian
DelMar Pharmaceuticals, Inc.
April 24, 2019
Page 2



       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Christine Westbrook at 202-551-5019 or Joe McCann at
202-551-6262
with any questions.



                                                           Sincerely,
FirstName LastNameSaiid Zarrabian
                                                           Division of
Corporation Finance
Comapany NameDelMar Pharmaceuticals, Inc.
                                                           Office of Healthcare
& Insurance
April 24, 2019 Page 2
cc:       Steven M. Skolnick, Esq.
FirstName LastName